Welcome to our dedicated page for CLABD news (Ticker: CLABD), a resource for investors and traders seeking the latest updates and insights on CLABD stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect CLABD's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of CLABD's position in the market.
Core One Labs Inc. (OTC: CLABF) announced its subsidiary, Vocan Biotechnologies, has optimized a biosynthetic production system for psilocybin, filing a patent application with the USPTO. This system allows bacteria to produce psilocybin cost-effectively, retaining the natural molecular structure. The patent covers methods for producing cGMP API grade psilocybin, targeting pharmaceutical companies and clinical trials. Dr. Hancock, CEO of Vocan, emphasized that this breakthrough positions Core One as a potential market leader in biosynthetic psychedelics, aiming to enhance mental health treatments.
Core One Labs (OTC: CLABD) has rescheduled its special investor webcast to January 21, 2022, at 1:30 p.m. PST. This adjustment allows Dr. Robert E.W. Hancock and his team from Vocan Biotechnologies to incorporate recent developments into their presentation. Participants can submit questions in advance, and a recording will be available shortly after the live event. Core One focuses on developing psychedelic medications through innovative delivery systems and aims to achieve regulatory approval for its psychedelic-derived treatments, leveraging a significant patient database.
Core One Labs Inc. (CSE: COOL, OTC: CLABD) announced a special investor webcast led by CEO Dr. Robert E.W. Hancock on January 18, 2022, at 1:30 p.m. PST. Participants can submit questions in advance via email. To register for the live event, visit the provided link. A recording will be available on the company’s website post-event. Core One focuses on developing psychedelic medicines and holds a patent-pending technology for delivering these compounds effectively. The company is advancing research for psychedelic-derived treatments for mental health disorders.
Core One Labs Inc. has made significant advancements in biosynthesizing N,N-Dimethyltryptamine (DMT), now approved by Health Canada for addition to its existing Dealer's Licence. With this approval, its subsidiary Vocan Biotechnologies Inc. aims to replicate the successful manufacturing of API-grade psilocybin to produce DMT. The engineering processes mirror those used for psilocybin, potentially speeding up patent filings for this psychedelic compound. The company is optimistic about using these advancements to expand its psychedelic production pipeline.
Core One Labs Inc. applauds Health Canada's amendment to the Special Access Programme (SAP), effective January 5, 2022, allowing physicians to request patient access to psychedelic treatments for serious conditions. This change marks a historic milestone in Canada's approach to mental health care, facilitating access to potentially life-saving medications for patients with treatment-resistant disorders. Additionally, Core One has lifted pooling restrictions on 5,814,000 common shares linked to its acquisition of New Path Laboratories and granted 2,144,000 Restricted Share Units under its plan.
Core One Labs has completed the acquisition of New Path Laboratories, enhancing its presence in the functional mushroom market. New Path specializes in natural health products and dietary supplements derived from functional mushrooms, utilizing a vertical integration model for low-cost production. The acquisition involves issuing 5,700,000 common shares, with a structured release over nine months. Joel Shacker, CEO, noted the acquisition's potential to generate sales revenue through expanded retail distribution channels, targeting the growing consumer demand for functional mushrooms.
Core One Labs Inc. (OTC: CLABD) applauds Seattle's city council for decriminalizing naturally occurring entheogenic drugs, including psilocybin, for personal and spiritual use. This makes Seattle the largest U.S. city to adopt such measures, joining nine others that have eased restrictions on psychedelics. The initiative aims to foster research and therapeutic use of these substances. Additionally, the company plans to issue 111,112 shares at $1.71 each to settle $190,000 in debt. The upcoming Annual General Meeting is scheduled for October 28, 2021, with a proxy submission deadline on October 26.
Core One Labs Inc. (OTC: CLABD) has partnered with its subsidiaries, Rejuva and Bluejay, to assist patients in applying for exemptions under Canada’s Controlled Drugs and Substances Act for legally accessing psilocybin for therapeutic purposes. This collaboration aims to increase access to psychedelic medicine for mental health treatment. Bluejay's GreenLeaf Medical Clinic is well-positioned to be among the first to secure such exemptions, reflecting Core One’s commitment to advancing psychedelic treatments and establishing a patient base for its psilocybin therapies.
Core One Labs Inc. (OTC: CLABD) has announced progress in its clinical development for AKO001 and AKO003, targeted at treating ischemic stroke and depression. Its subsidiary, Akome Biotech Ltd., is currently selecting commercial research organizations to conduct necessary in vitro and in vivo studies. These steps are essential prior to human clinical trials. The company aims to utilize its patent-pending technology to enhance the delivery of psychedelic medications and secure regulatory approval for mental health treatments.
Core One Labs (CSE: COOL, OTC: CLABD) announced updates on its psilocybin technology at a Virtual Town Hall on August 4, 2021. The company is preparing to file a patent to protect its proprietary production method, which aims to lower psilocybin production costs significantly. Through a partnership with the University of British Columbia, Core One is optimizing its research capabilities. The company is focusing on developing a novel oral strip delivery system for psychedelic compounds, positioning itself for potential profitability in the emerging psychedelic medicine market.
